pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), ... versus ..., meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.97 [0.73, 1.28]< 156%2 studies (2/-)58.8 %lownot evaluable highcrucial-
progression or deaths (PFS) 0.81 [0.58, 1.14]< 172%2 studies (2/-)88.3 %lownot evaluable highimportant-
objective responses (ORR) 2.02 [0.84, 4.87]> 161%2 studies (2/-)94.2 %lownot evaluable highnon important-

safety endpoints 00

TRAE (any grade) 1.77 [1.07, 2.93]< 10%1 study (1/-)1.3 %NAnot evaluable non important-
TRAE (grade 3-4) 1.68 [1.23, 2.28]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.88 [0.43, 8.18]< 10%2 studies (2/-)20.1 %some concernnot evaluable moderatenon important-
TRAE leading to discontinuation (any grade) 3.74 [0.76, 18.52]< 10%1 study (1/-)5.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons